NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 9 November 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien [Topics 1 & 3 Chair] Present for all items
2. Dr Peter Selby [Topic 2 Chair] Present for all items
3. Dr Alex Cale Items 1 to 5.2.2
4. Dr Charles Crawley [non-voting member] Present for all items
5. Michael Chambers Present for all items
6. Dr Prithwiraj Das Items 1 to 4.2.2 & 6.1.3 to 6.2.2
7. Dr Rob Forsyth Present for all items
8. Dr Natalie Hallas Items 1 to 5.2.2
9. John Hampson Present for all items
10. Dr Nigel Langford Present for all items
11. Iain McGowan Items 5 to 6.2.2
12. Dr Mudasar Mushtaq Present for all items
13. Dr Richard Nicholas Present for all items
14. Ugochi Nwulu Present for all items
15. Stella O’Brien Present for all items
16. Professor Subhash Pokhrel Present for all items
17. Professor Andrew Renehan Items 1 to 4.2.2 & 6 to 6.2.2
18. Professor Matt Stevenson Items 1 to 4.2.2 & 6 to 6.2.2
19. Professor Paul Tappenden Present for all items

NICE staff present

Ross Dent, Associate Director Items 1 to 4.2.2 & 6 to 6.2.2

Linda Landells, Associate Director Items 5 to 5.2.2

Louise Jafferally, Project Manager Items 1 to 4.2.2 & 6 to 6.2.2

Kate Moore, Project Manager Items 1 to 4.1.2, 5 to 5.2.2 & 6 to 6.1.3

Victoria Kelly, Health Technology Assessment Adviser Items 1 to 4.2.2

Hannah Nicholas, Health Technology Assessment Adviser Items 5 to 5.2.2

Alexandra Filby, Health Technology Assessment Adviser Items 6 to 6.2.2

Fatima Chunara, Health Technology Assessment Analyst Items 1 to 4.2.2

Anita Sanga, Health Technology Assessment Analyst Items 5 to 5.2.2

Kirsty Pitt, Health Technology Assessment Analyst Items 6 to 6.2.2

Benjamin Gregory, Business Analyst, RIA Present for all items

Benjamin Pearce, Senior Medical Editor Items 1 to 4.2.2

Sarah Bromley, Senior Medical Editor Items 5 to 5.2.2

Helen Barnett, Senior Medical Editor Items 6 to 6.2.2

Ella Livingstone, Technical Adviser, Commercial Risk Assessment Items 1 to 4.2.2 & 6 to 6.2.2

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment Items 1 to 4.2.2 & 6 to 6.2.2

Claire Hawksworth, Technical Analyst, Evidence Generation Items 6 to 6.2.2

Steve Norton, Technical Analyst, Evidence Generation Items 1 to 4.2.2

Benjamin Purchase, Senior Scientific Adviser, Scientific Advice Items 1 to 4.1.3

Mandy Tonkinson, Public Involvement Adviser, PIP Items 1 to 4.1.3 & 6 to 6.1.3

Lyn Davies, Coordinator, Corporate Office Items 5 to 5.1.3

Rosalee Mason, Coordinator, Corporate Office Items 5 to 5.1.3

Lucinda Evans, Coordinator, Corporate Office Items 6 to 6.1.3

Gemma Smith, Coordinator, COT Present for all items

Iain Cannell, Administrator, TA Items 1 to 4.2.2 & 6 to 6.2.2

Celia Mayers, Administrator, TA Items 5 to 5.2.2

External review group representatives present

Robert Hodgson, Centre for Reviews and Dissemination and Centre for Health Economics -York, Items 1 to 4.1.3

Lucy Beresford, Centre for Reviews and Dissemination and Centre for Health Economics -York, Items 1 to 4.1.3

Rachel Houten, Liverpool Reviews, and Implementation Group Items 5 to 5.1.3

James Mahon, Liverpool Reviews, and Implementation Group Items 5 to 5.1.3

Graham Scotland, Aberdeen HTA Group Items 6 to 6.1.3

Charlotte Kennedy, Aberdeen HTA Group Items 6 to 6.1.3

Clinical & patient experts present

Professor Peter Clark, National Clinical Lead for Cancer drugs fund, NHS England,

Items 1 to 4.2.2 & 6 to 6.2.2

Dr Rakesh Popat, Consultant Haematologist & Honorary Associate Professor, clinical expert nominated by Janssen-Cilag Ltd, Items 1 to 4.1.3

Dr Matthew Streetley, Consultant Haematologist & Advocacy Lead UKMF, clinical expert nominated by UK Myeloma Forum, Items 1 to 4.1.3

Shelagh McKinlay, Patient expert nominated by Myeloma UK, Items 1 to 4.1.3

Stuart Fullerton, Patient expert nominated by Myeloma UK, Items 1 to 4.1.3

Dr Mike Dennis, Consultant Haematologist, clinical expert nominated by Royal College of Physicians, Items 6 to 6.1.3

Dr Elspeth Payne, Associate Clinical Professor & Consultant haematologist, clinical expert nominated by The Royal College of Pathologists, Items 6 to 6.1.3

Charlotte Martin, Patient expert nominated by Leukaemia Care, Items 6 to 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Steven O’Brien welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee noted the minutes of the meeting held on Wednesday 13 October 2021. Committee were reminded of the deadline for comments and that these minutes would be confirmed and uploaded following the 16 November deadline.

### Appraisal of ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID3816]

* 1. Part 2a – Closed session [No public in attendance]
		1. The chair Professor Steven O’Brien welcomed the invited clinical and patient experts, external review group representatives, the National Clinical lead for Cancer drugs fund and company representatives from Janssen.
		2. The chair asked all committee members, clinical and patient experts, external review group representatives the National Clinical lead for Cancer drugs fund and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Richard Nicholas declared financial interests as he has attended paid advisory boards with Novartis in an unrelated area [MS].
* It was agreed that his declaration would not prevent Dr Nicholas from participating in this section of the meeting.
* Nominated clinical expert Dr Rakesh Popat declared financial interests as he has received fees for consultancy, talks and support to attend conferences from Janssen.
* It was agreed that his declaration would not prevent Dr Popat from providing expert advice to the committee.
* Nominated clinical expert Dr Matthew Streetley declared financial interests as he has attended advisory boards for Celgene, BMS, Takeda and Janssen-Cilag.
* It was agreed that his declaration would not prevent Dr Streetley from providing expert advice to the committee.
* Nominated patient experts Stuart Fullerton and Shelagh McKinley declared indirect financial interests as Myeloma UK has received grants and project specific funding from Amgen, Celgene and Janssen-Cilag and gifts, honoraria, and sponsorship from Celgene, Janssen-Cilag and Novartis.
* It was agreed that their declaration would not prevent them from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team, Dr Nigel Langford, Professor Paul Tappenden and Ugochi Nwulu.
	1. Part 2b – Closed session [company representatives, clinical and patient experts and external review group representatives were asked to leave the meeting]
		1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or the Final Appraisal Determination [FAD]. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or the Final Appraisal Determination [FAD] in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10806> .

### Appraisal of pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]

* 1. Part 1 – Open session
		1. The chair Dr Peter Selby welcomed the external review group representatives, members of the public and company representatives from Swedish Orphan Biovitrum.
		2. The chair asked all committee members, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor Matt Stevenson was paid to provide advice for comparator company Alexion related to its submission for ravulizumab. As a direct conflict Professor Stevenson did not participate in discussions for this appraisal.
* Committee member Dr Prithwiraj Das declared that he works at AstraZeneca as the Head of Market Access for Respiratory, Immunology, Vaccines, and Infectious Diseases and comparator company Alexion is now part of the AstraZeneca group. As a direct conflict Dr Das did not participate in discussions on this appraisal.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session [company representatives, external review group representatives and members of the public were asked to leave the meeting].
		1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD] in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10651>

### Appraisal of venetoclax with a hypomethylating agent for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable [ID1564]

* 1. Part 1 – Open session
		1. The chair Professor Stephen O’Brien welcomed the invited clinical & patient experts, external review group representatives, the National Clinical lead for Cancer drugs fund, members of the public and company representatives from AbbVie.
		2. The chair asked all committee members, clinical & patient experts, external review group representatives, the National Clinical lead for Cancer drugs fund and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has attended an advisory Board for Pfizer in an unrelated disease area.
* It was agreed that his declaration would not prevent Michael from participating in this section of the meeting.
* Nominated patient expert Charlotte Martin declared direct non-financial interests as she has been an employee of Leukaemia Care since June 2018.
* It was agreed that her declaration would not prevent Charlotte from providing expert advice to the committee.
* Nominated clinical expert Dr Elspeth Payne declared financial interests as she has received honoraria for talks and advisory boards from Celgene, a BMS company.
* It was agreed that her declaration would not prevent Dr Payne from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session [company representatives, clinical & patient experts, external review group representatives and members of the public were asked to leave the meeting].
		1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or the Final Appraisal Determination [FAD]. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or the Final Appraisal Determination [FAD] in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10478>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 14 December 2021 and will start promptly at 09.30.